Sharon O’Reilly, founder of Medtech Insight and originator of the “Investment In Innovation (In3)” conference series, in conjunction with Michael Mack, MD, a widely known heart surgeon, will host insynCVentures, a one-day all-cardiovascular strategic partnering and investment conference on April 22 at the Westin Galleria Dallas, immediately before the Dallas-Leipzig International Valve Congress.

“Uncertain economic times have made funding for medical device start-ups even more challenging, and getting in front of the right people is the key to opening the door to funding, partnering and investment opportunities,” O’Reilly said.
“The insynCVentures conference is designed specifically to help emerging companies gain access to the most important dealmakers in the CV industry — both major device manufacturers and investment firms—who are actively seeking opportunities for funding, acquisition, and strategic partnerships.”

This conference will be rich and deep with executives and investors from major CV companies and investment firms,” according to O’Reilly. “If an emerging CV company wants to gain access to the dealmakers that matter the most to them, insynCVentures is the conference to attend.”

The program will feature presentations from 30+ emerging companies focused solely on the interventional cardiology, cardiac surgery, neurointerventional and peripheral vascular markets — all seeking funding and strategic partnerships.
The event will kick off with a keynote presentation by Dr. Thomas Fogarty, renowned cardiac surgeon, inventor and founder of more than 30 device companies, entitled “Will the U.S. Maintain its Position as a World Leader in Medical Technology?” Also planned is a panel discussion titled “Where the Money Is: Alternative Sources of Financing.”

Presenting companies will have unlimited exhibit time during the entire conference to network with potential partners.
The insynCVentures conference will bring key dealmakers together in the cardiovascular arena — ranging from CEOs, Business Development and Marketing VPs, Entrepreneurs and Venture Capitalists. Early-stage companies developing technologies in the areas of Biologics and Regenerative Medicine; Cardiovascular Diagnostics; Cardiovascular Surgery; Interventional Cardiology; Electrophysiology; Heart Failure; Peripheral Vascular Interventions; and Stroke should not miss this opportunity.

For more information, see insyncventuresconference.com.